| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/18/1998 | CA2274682A1 N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate |
| 06/18/1998 | CA2273988A1 Novel heterocyclically substituted benzamides and their use in fighting diseases |
| 06/18/1998 | CA2272089A1 17.alpha.-dihydroequilenin for use as a medical antioxidant |
| 06/18/1998 | CA2272087A1 Use of equilenin as an antioxidant |
| 06/18/1998 | CA2272074A1 Use of 17.beta.-dihydroequilenin as an antioxidant |
| 06/18/1998 | CA2263828A1 Polyprolyl inhibitors of cyclophilin |
| 06/17/1998 | EP0848061A2 Self-enhancing, pharmacologically controllable expression systems |
| 06/17/1998 | EP0848060A2 Novel human 11CB splice variant |
| 06/17/1998 | EP0847999A1 N-benzylpiperazine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 06/17/1998 | EP0847990A1 4-(C1-C4)-Alkoxy-3-pyrrolin-2-on-1-yl-acetic acid derivatives, their preparation and use in the synthesis of 4-hydroxy-2-oxo-pyrrolidin-1-yl-acetamide |
| 06/17/1998 | EP0847395A1 Pyrrolyl tetrahydroquinoxalin diones, their production and use in the treatment of diseases |
| 06/17/1998 | EP0847391A1 Aromatic compounds and pharmaceutical compositions containing them |
| 06/17/1998 | EP0847275A1 Regulation of intracellular glucocorticoid concentrations |
| 06/17/1998 | EP0714389B1 Amide and urea derivatives as 5ht1d receptor antagonists |
| 06/17/1998 | EP0666847B1 Tryptamine analogs with 5-ht1d selectivity |
| 06/17/1998 | EP0635003B1 Perhydroisoindole derivatives as p substance antagonists |
| 06/17/1998 | CN1185152A Pyrrolidinyl methyl indole salt |
| 06/17/1998 | CN1185108A Method for treating cognitive dysfunction |
| 06/17/1998 | CN1184671A Traditional Chinese medicine for treating vegetative nerve functional disturbance |
| 06/17/1998 | CA2224835A1 Pharmaceutical compounds |
| 06/16/1998 | US5767280 Hydroxylation of a thio-substituted 1,2,5-thiadiazole with an aqueous alkaline metal hydroxide; acidification |
| 06/16/1998 | US5767240 Activity-dependent neurotrophic factor |
| 06/16/1998 | US5767132 Pyridyl chroman |
| 06/16/1998 | US5767128 1,3-dihydro-2H-pyrrolo 2,3-b!pyridin-2-one compounds |
| 06/16/1998 | US5767126 Alzheimer's disease treatment with tacrine metabolites |
| 06/16/1998 | US5767119 Method of treating neurodegenerative diseases using an AMPA excitatory amino and an uricosuric agent |
| 06/16/1998 | US5767117 Method for treating vascular headaches |
| 06/16/1998 | US5767116 Bicyclic aromatic compounds as therapeutic agents |
| 06/16/1998 | US5767088 Useful for treating pain, inflammation, smooth muscle contraction and inducing vasodilation |
| 06/16/1998 | US5767085 Peptide derivatives |
| 06/16/1998 | US5767083 Inhibition of melanocyte stimulatting hormone |
| 06/16/1998 | US5766948 Culturing neuroblast cells in vessel in serum-free basal medium supplemented with basic fibroblast growth factor, wherein surface of vessel allows attachment of cells |
| 06/16/1998 | US5766886 Modified antibody variable domains |
| 06/16/1998 | US5766596 Aconite tuber-sulphur composite preparation and a process for the preparation thereof |
| 06/16/1998 | CA1339917C New potically-active derivatives of (r) 5-pentylamino- 5- oxopentanoic acid with antagonistic activity towards cholecystokinin and a method for their preparation |
| 06/11/1998 | WO1998024916A1 Novel calpaines, production and use thereof |
| 06/11/1998 | WO1998024914A1 Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy |
| 06/11/1998 | WO1998024905A2 Secreted proteins and polynucleotides encoding them |
| 06/11/1998 | WO1998024900A1 Human g-protein receptor hcegh45, a pacap-like (g-protein pituitary adenylate cyclase activating polypeptide-like) receptor |
| 06/11/1998 | WO1998024898A2 Therapeutic composition comprising the kal protein and use of the kal protein |
| 06/11/1998 | WO1998024810A2 Vertebrate homologues of unc-53 protein of c. elegans |
| 06/11/1998 | WO1998024805A1 INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
| 06/11/1998 | WO1998024804A2 INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
| 06/11/1998 | WO1998024790A1 1,4-diazabicyclo [2.2.2] oct-2-ylmethyl derivatives, their preparation and therapeutic application |
| 06/11/1998 | WO1998024788A1 Tropane derivatives and method for their synthesis |
| 06/11/1998 | WO1998024785A1 Indole-urea derivatives with 5-ht antagonist properties |
| 06/11/1998 | WO1998024783A1 Novel n-benzenesulphonyl-l-proline derivatives, method for preparing and therapeutic use |
| 06/11/1998 | WO1998024782A2 Substituted pyrimidine compounds and their use |
| 06/11/1998 | WO1998024780A2 Substituted pyrimidinone and pyridinone compounds and their use |
| 06/11/1998 | WO1998024766A1 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors |
| 06/11/1998 | WO1998024765A1 Novel substituted tetrahydropyridin derivatives, method of preparation and pharmaceutical compositions containing them |
| 06/11/1998 | WO1998024762A1 Vitamin d3 derivatives |
| 06/11/1998 | WO1998024465A1 Wound healing and treatment of fibrosis |
| 06/11/1998 | WO1998024461A1 Peptide synthesis with sulfonyl protecting groups |
| 06/11/1998 | WO1998024448A1 METHOD OF PREVENTING NEURODEGENERATION AND COGNITIVE DYSFUNCTION USING 17α-DIHYDROEQUILENIN |
| 06/11/1998 | WO1998024447A1 Use of nk-1 receptor antagonists for treating cognitive disorders |
| 06/11/1998 | WO1998024446A1 Use of nk-1 receptor antagonists for treating movement disorders |
| 06/11/1998 | WO1998024445A1 Use of nk-1 receptor antagonists for treating schizophrenic disorders |
| 06/11/1998 | WO1998024444A1 Use of nk-1 receptor antagonists for treating substance use disorders |
| 06/11/1998 | WO1998024443A1 Use of nk-1 receptor antagonists for treating bipolar disorders |
| 06/11/1998 | WO1998024441A1 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
| 06/11/1998 | WO1998024440A1 Use of nk-1 receptor antagonists for treating stress disorders |
| 06/11/1998 | WO1998024439A1 Use of nk-1 receptor antagonists for treating severe anxiety disorders |
| 06/11/1998 | WO1998024438A1 Use of nk-1 receptor antagonists for treating major depressive disorders |
| 06/11/1998 | WO1998024435A1 Use of 2-(4-methoxyphenyl)-pyrazolo(4,3-c)quinolin-3-one in the manufacture of a medicament for enhancing cognition |
| 06/11/1998 | WO1998024433A1 Application of thalidomide to the treatment of parkinson's disease and parkisonian syndromes |
| 06/11/1998 | WO1998024430A1 Pharmaceutical compositions containing n-sulphonyl indolin derivatives |
| 06/11/1998 | WO1998024427A2 Compositions and methods for treating or preventing inflammatory diseases |
| 06/11/1998 | CA2607067A1 Compositions and methods for treating or preventing inflammatory diseases |
| 06/11/1998 | CA2274316A1 Therapeutic composition comprising the kal protein and use of the kal protein for the treatment of retinal, renal, neuronal and neural injury |
| 06/11/1998 | CA2274304A1 Novel calpaines, production and use thereof |
| 06/11/1998 | CA2274250A1 Inhibitors of interleukin-1.beta. converting enzyme |
| 06/11/1998 | CA2274249A1 Inhibitors of interleukin-1.beta. converting enzyme |
| 06/11/1998 | CA2274011A1 Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy |
| 06/11/1998 | CA2274002A1 Wound healing and treatment of fibrosis |
| 06/11/1998 | CA2273990A1 Pharmaceutical compositions containing n-sulphonyl indolin derivatives |
| 06/11/1998 | CA2273857A1 Peptide synthesis with sulfonyl protecting groups |
| 06/11/1998 | CA2273856A1 Use of nk-1 receptor antagonists for treating bipolar disorders |
| 06/11/1998 | CA2273853A1 Use of nk-1 receptor antagonists for treating cognitive disorders |
| 06/11/1998 | CA2273845A1 Secreted proteins and polynucleotides encoding them |
| 06/11/1998 | CA2273827A1 Vertebrate homologues of unc-53 protein of c. elegans |
| 06/11/1998 | CA2273810A1 Use of nk-1 receptor antagonists for treating major depressive disorders |
| 06/11/1998 | CA2273809A1 Use of nk-1 receptor antagonists for treating movement disorders |
| 06/11/1998 | CA2273807A1 Use of nk-1 receptor antagonists for treating schizophrenic disorders |
| 06/11/1998 | CA2273806A1 Use of nk-1 receptor antagonists for treating substance use disorders |
| 06/11/1998 | CA2273800A1 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
| 06/11/1998 | CA2273786A1 Use of nk-1 receptor antagonists for treating stress disorders |
| 06/11/1998 | CA2273785A1 Use of nk-1 receptor antagonists for treating severe anxiety disorders |
| 06/11/1998 | CA2273198A1 Human g-protein receptor hcegh45, a pacap-like (g-protein pituitary adenylate cyclase activating polypeptide-like) receptor |
| 06/11/1998 | CA2272891A1 Method of preventing neurodegeneration and cognitive dysfunction using 17.alpha.-dihydroequilenin |
| 06/11/1998 | CA2272470A1 Use of 2-(4-methoxyphenyl)-pyrazolo(4,3-c)quinolin-3-one in the manufacture of a medicament for enhancing cognition |
| 06/11/1998 | CA2272148A1 Vitamin d3 derivatives |
| 06/11/1998 | CA2271072A1 1,4-diazabicyclo [2.2.2] oct-2-ylmethyl derivatives, their preparation and therapeutic application |
| 06/11/1998 | CA2224334A1 Self-enhancing, pharmacologically controllable expression systems |
| 06/11/1998 | CA2224131A1 Novel human 11 cb splice variant |
| 06/10/1998 | EP0846764A2 Glial cell line-derived neurotrophic factor alpha receptor family |
| 06/10/1998 | EP0846689A1 Benzimidazole compounds |
| 06/10/1998 | EP0846688A1 New imidazoline derivatives having affinity for the imidazoline receptor |
| 06/10/1998 | EP0846465A1 Remedy for anxiety neurosis |
| 06/10/1998 | EP0846464A2 Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia |